Clinical Trials Logo

Clinical Trial Summary

The finding that ischemia-modified albumin (IMA) is increased in pre-eclamptic pregnancy suggests a role for IMA as a potential biomarker for abnormal placental development related to miscarriage.This study was undertaken to evaluate IMA levels in women with recurrent pregnancy loss (RPL).


Clinical Trial Description

Ischemia-modified albumin (IMA) measured by the albumin cobalt binding test is a relatively new biomarker in the identification of myocardial ischemia. Experimental studies have shown that pregnancies normally develop in a relatively hypoxic intrauterine environment, and the subsequent reperfusion and oxidative stress is important for physiological trophoblast development. The finding that maternal serum IMA levels are raised so early in pregnancy provides further support for IMA as a potential marker for abnormal placental development that may be related to early pregnancy loss. In this study, we aimed to evaluate maternal circulating IMA levels in women with RPL by comparing them with healthy controls. ;


Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


NCT number NCT01988740
Study type Observational
Source Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Contact hediye dagdeviren, md
Phone 5079872463
Email hediyedagdeviren@gmail.com
Status Recruiting
Phase N/A
Start date November 2013
Completion date April 2014

See also
  Status Clinical Trial Phase
Terminated NCT01011634 - Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions Phase 4
Active, not recruiting NCT04707456 - Comparative Study of Learning Curve for First Trimester Fetal Anomaly Scan N/A
Completed NCT01933360 - Misoprostol for Cervical Priming Prior to Vacuum Aspiration Phase 2